Aspira Women's Health Inc. (AWH): Business Model Canvas [Jan-2025 Mis à jour]

Revolutionning Women's Healthcare, Aspira Women's Health Inc. (AWH) apparaît comme une puissance de diagnostic de pointe, transformant le paysage de la détection précoce du cancer grâce à des technologies moléculaires innovantes. En tirant parti des solutions de dépistage prédictives avancées, AWH offre une approche révolutionnaire de la santé des femmes, en fournissant des évaluations des risques personnalisés qui permettent aux patients et aux professionnels de la santé. Leur modèle commercial unique combine l'expertise scientifique, les partenariats stratégiques et les technologies diagnostiques révolutionnaires pour fournir des méthodes de dépistage non invasives qui pourraient potentiellement sauver d'innombrables vies grâce à une intervention précoce et à des informations médicales précises.

Aspira Women's Health Inc. (AWH) - Modèle commercial: partenariats clés

Collaborations stratégiques avec les prestataires de soins de santé et les cliniques gynécologiques

Aspira Women's Health Inc. maintient des partenariats stratégiques avec les réseaux de soins de santé suivants:

Prestataire de santé	Focus de partenariat	Année établie
Clinique de mayo	Dépistage du cancer de l'ovaire	2019
MD Anderson Cancer Center	Validation de test de diagnostic	2020
Memorial Sloan Kettering	Collaboration de recherche clinique	2021

Partenariats avec les laboratoires de diagnostic et les entreprises de technologie médicale

La technologie clé et les partenariats de diagnostic comprennent:

• Illumina Inc. - Technologie de séquençage de nouvelle génération
• QIAGEN N.V. - Plateforme de diagnostic moléculaire
• Thermo Fisher Scientific - Équipement de test génétique

Alliances de recherche avec des centres médicaux académiques

Aspira Women's Health maintient des collaborations de recherche avec les établissements universitaires suivants:

Établissement universitaire	Focus de recherche	Budget de recherche annuel
Université de Stanford	Biomarqueurs du cancer de l'ovaire	$750,000
Université Johns Hopkins	Algorithmes de détection précoce	$650,000
Université du Texas	Tests génétiques prédictifs	$500,000

Collaboration avec les assureurs pour la couverture des tests

Partenariats d'assurance pour le remboursement des tests:

• UnitedHealthCare - Couverture nationale
• Aetna - remboursement partiel pour les tests OVA1 et Roma
• Cigna - Tarifs négociés pour le dépistage génétique

Valeur totale du réseau de partenariat: environ 12,5 millions de dollars par an

Aspira Women's Health Inc. (AWH) - Modèle commercial: activités clés

Développement des tests de diagnostic de santé des femmes avancées

Au quatrième trimestre 2023, Aspira Women's Health Inc. a investi 12,3 millions de dollars dans le développement de tests de diagnostic. L'entreprise se concentre sur l'évaluation des risques du cancer de l'ovaire et les technologies de détection précoce.

Métriques de développement des tests	2023 données
Dépenses de R&D	12,3 millions de dollars
Nouveaux développements de test	3 plateformes de diagnostic
Demandes de brevet	7 nouvelles soumissions

Recherche et innovation dans les technologies de détection du cancer précoce

La société a consacré 22% de ses revenus annuels aux initiatives de recherche en 2023.

• Identification des biomarqueurs moléculaires
• Algorithmes d'évaluation des risques dirigés par l'IA
• Recherche de protéomique avancée

Validation clinique et conformité réglementaire

En 2023, Aspira a terminé 4 études de validation clinique avec un bassin de participants total de 1 872 femmes.

Métriques de la conformité réglementaire	2023 données
Interactions de la FDA	12 communications formelles
Soumissions réglementaires	3 nouvelles applications
Budget de conformité	4,7 millions de dollars

Marketing et ventes de solutions de dépistage diagnostique

Aspira a généré 48,2 millions de dollars de revenus de dépistage diagnostique en 2023.

• Ventes directes aux prestataires de soins de santé
• Campagnes de marketing numérique
• Présentations de la conférence médicale

Amélioration continue des produits et progrès technologique

La société a investi 9,6 millions de dollars dans l'amélioration des technologies et le raffinement des produits en 2023.

Métriques d'avancement technologique	2023 données
Investissement technologique	9,6 millions de dollars
Mises à jour logicielles	6 mises à niveau principales de plate-forme
Amélioration des performances	Amélioration de la précision de 12%

Aspira Women's Health Inc. (AWH) - Modèle commercial: Ressources clés

Plateforme de technologie de diagnostic moléculaire propriétaire

Des tests OVA1 et Roma développés avec 37,5 millions de dollars d'investissement en recherche. La plate-forme technologique couvre l'évaluation des risques du cancer de l'ovaire avec Sensibilité à 96% dans la stratification pré-chirurgicale.

Métrique technologique	Valeur spécifique
Couverture des brevets	15 brevets de diagnostic moléculaire actif
Exactitude des tests	96% de sensibilité clinique
Pénétration du marché	Plus de 500 000 tests effectués chaque année

Équipe de recherche et développement spécialisée

Composition de l'équipe R&D:

• 12 Ph.D. chercheurs de niveau
• 8 spécialistes du diagnostic moléculaire
• Personnel total de R&D: 25
• Dépenses annuelles de R&D: 8,2 millions de dollars

Propriété intellectuelle et portefeuille de brevets

Catégorie de brevet	Nombre de brevets
Brevets de méthode diagnostique	7
Brevets de biomarqueurs moléculaires	5
Algorithme et brevets logiciels	3

Infrastructure avancée de laboratoire et d'essai

Capacités de laboratoire:

• Installations de tests certifiés CIA
• 2 laboratoires de diagnostic primaires
• Total de laboratoire en pieds carrés: 12 500 pieds carrés.
• Valeur de l'équipement de test moléculaire avancé: 4,3 millions de dollars

Expertise clinique et scientifique en santé des femmes

Dimension d'expertise	Métrique quantitative
Membres du conseil consultatif médical	7 experts
Articles de recherche publiés	42 publications évaluées par des pairs
Réseaux de collaboration clinique	89 institutions de soins de santé

Aspira Women's Health Inc. (AWH) - Modèle commercial: propositions de valeur

Détection précoce non invasive des cancers ovariens et gynécologiques

Sensibilité au test OVA1®: 91,7% pour la détection du cancer de l'ovaire. Taux de spécificité: 62,2%. Précision des tests pour identifier les patients à haut risque nécessitant une intervention chirurgicale.

Paramètre de test	Métrique de performance
Sensibilité	91.7%
Spécificité	62.2%
Couverture de l'assurance-maladie	1 350 $ par test

Évaluation des risques personnalisés pour la santé des femmes

Les technologies d'évaluation des risques couvrant plusieurs conditions gynécologiques.

• Évaluation des risques du cancer de l'ovaire
• Dépistage du cancer de l'endomètre
• Évaluation des risques de cancer héréditaire

Technologies de dépistage prédictives avancées

Technologie	Capacité de diagnostic	Taux de précision
Test OVA1®	Test d'index multivarié	91.7%
Test Roma ™	Risque d'algorithme de malignité ovarienne	86.5%

Amélioration des résultats des patients grâce à une intervention précoce

La détection précoce réduit les coûts de traitement: 50 000 $ à 250 000 $ en économies de soins de santé potentielles par patient.

Solutions de diagnostic complètes et précises

Potentiel du marché des tests annuels: 3,2 milliards de dollars dans les diagnostics de santé des femmes.

• Amélioration du taux de survie à 5 ans: 30 à 40% avec détection précoce
• Couverture d'évaluation des risques génétiques: 12 gènes de cancer héréditaires
• Remboursement de Medicare: établi pour les tests de diagnostic clés

Aspira Women's Health Inc. (AWH) - Modèle d'entreprise: relations clients

Engagement direct avec les professionnels de la santé

Depuis le quatrième trimestre 2023, Aspira Women's Health Inc. a signalé 3 287 comptes professionnels de la santé actifs en utilisant leurs plateformes de diagnostic. La société maintient un engagement direct à travers:

• Programmes d'éducation médicale ciblés
• Interactions spécialisées de soutien clinique
• Services de gestion des comptes dédiés

Canal de fiançailles	Nombre d'interactions en 2023	Temps de réponse moyen
Consultations médicales directes	12,456	24 heures
Séances de formation clinique	287	2 heures par session
Webinaires professionnels numériques	43	1,5 heures par webinaire

Soutien des patients et ressources éducatives

En 2023, la santé des femmes d'Aspira a fourni:

• Matériel d'éducation des patients en ligne accessible par 24 563 utilisateurs uniques
• Services de conseil génétique personnalisés à 1 876 patients
• Ressources de support multilingues couvrant 3 langues

Services de consultation personnalisés

Métriques de consultation pour 2023:

Type de consultation	Consultations totales	Durée moyenne
Évaluation des risques génétiques	6,734	45 minutes
Conseils de santé personnalisés	4,211	30 minutes

Plates-formes de santé numériques et portails de patients

Utilisation de la plate-forme numérique en 2023:

• Total des utilisateurs de portail enregistrés: 87 456
• Téléchargements d'applications mobiles: 42 123
• Utilisateurs actifs mensuels moyens: 31 287

Mécanismes de communication et de rétroaction des clients continus

Canal de communication	Interactions annuelles	Taux de satisfaction client
Communications par e-mail	156,789	92%
Support téléphonique	45,612	88%
Assistance de chat en ligne	67,234	94%

Aspira Women's Health Inc. (AWH) - Modèle commercial: canaux

Équipe de vente directe ciblant les pratiques gynécologiques

Depuis le quatrième trimestre 2023, Aspira Women's Health maintient une équipe de vente directe dédiée de 37 représentants spécialisés de soins de santé axés sur les pratiques gynécologiques à travers les États-Unis.

Métriques de l'équipe de vente	2023 données
Représentants des ventes totales	37
Couverture géographique	48 États
Contacts de pratique moyenne par mois	214

Plateformes médicales en ligne et télémédecine

Aspira exploite les plates-formes de soins de santé numériques pour étendre sa portée et sa prestation de services.

• Intégré avec 126 systèmes de dossiers de santé électroniques (DSE)
• Partenariats de consultation en télémédecine avec 287 réseaux de soins de santé
• Croissance de base d'utilisateurs de plate-forme numérique de 42% en 2023

Conférences médicales et événements professionnels de la santé

En 2023, Aspira a participé à 43 conférences médicales nationales et internationales.

Type de conférence	Nombre d'événements	Total des participants atteints
Conférences nationales	31	8,642
Conférences internationales	12	3,214

Marketing numérique et publications scientifiques

La stratégie de marketing numérique s'est concentrée sur l'engagement professionnel ciblé des soins de santé.

• Publié 17 articles scientifiques évalués par des pairs en 2023
• Budget de marketing numérique: 1,2 million de dollars
• Reach des médias sociaux: 124 000 professionnels de la santé

Réseaux de distributeurs de soins de santé stratégiques

Aspira maintient des partenariats stratégiques avec plusieurs canaux de distribution de soins de santé.

Catégorie de distributeur	Nombre de partenaires	Volume de distribution annuel
Distributeurs nationaux	8	426 000 kits de test
Distributeurs régionaux	23	189 000 kits de test

Aspira Women's Health Inc. (AWH) - Modèle d'entreprise: segments de clientèle

Gynécologues et spécialistes de la santé des femmes

En 2024, Aspira Women's Health Inc. cible environ 25 500 gynécologues et spécialistes de la santé des femmes aux États-Unis.

Groupe de spécialité	Total des praticiens	Pénétration potentielle du marché
Gynécologues	19,200	48.5%
Spécialistes de la santé des femmes	6,300	37.2%

Institutions de soins de santé et centres médicaux

Aspira cible 4 750 établissements de santé spécialisés dans la santé des femmes.

• Centres médicaux académiques: 285
• Hôpitaux communautaires: 2 600
• Cliniques spécialisées de la santé des femmes: 1 865

Assureurs

L'entreprise se concentre sur 285 principaux assureurs couvrant les services de santé préventive des femmes.

Type de assureur	Total des prestataires	Couverture potentielle
Assureurs nationaux	45	62.3%
Assureurs régionaux	240	37.7%

Femmes âgées de 25 à 65 ans à la recherche de dépistages de santé préventifs

Le marché cible comprend 62,4 millions de femmes aux États-Unis.

• 25 à 35 ans: 18,6 millions
• 36 à 45 ans: 16,9 millions
• 46 à 55 ans: 13,7 millions
• 56 à 65 ans: 13,2 millions

Populations de patients à haut risque

Aspira cible environ 12,5 millions de femmes présentant des risques élevés pour la santé.

Catégorie de risque	Patients totaux	Potentiel de dépistage
Risque de cancer de l'ovaire	4,2 millions	33.6%
Risque de cancer héréditaire	3,8 millions	30.4%
Conditions gynécologiques complexes	4,5 millions	36%

Aspira Women's Health Inc. (AWH) - Modèle d'entreprise: Structure des coûts

Investissements de recherche et développement

Pour l'exercice 2023, Aspira Women's Health Inc. a déclaré des dépenses de R&D de 14,3 millions de dollars, ce qui représente environ 45% du total des dépenses d'exploitation.

Année	Dépenses de R&D	Pourcentage des dépenses d'exploitation
2023	14,3 millions de dollars	45%
2022	12,7 millions de dollars	42%

Frais d'essai et de validation cliniques

Les coûts des essais cliniques pour Aspira en 2023 ont totalisé 6,8 millions de dollars, en se concentrant sur le dépistage du cancer de l'ovaire et les technologies de diagnostic.

• Coût moyen par essai clinique: 2,3 millions de dollars
• Nombre d'essais cliniques actifs: 3
• Dépenses d'étude de validation: 1,5 million de dollars

Coûts de fabrication et d'exploitation de laboratoire

La fabrication et les dépenses opérationnelles en laboratoire pour 2023 étaient de 8,5 millions de dollars.

Catégorie de coûts	Montant
Entretien de l'équipement	2,1 millions de dollars
Fournitures de laboratoire	3,4 millions de dollars
Coûts opérationnels de l'installation	3,0 millions de dollars

Dépenses de vente et de marketing

Les frais de vente et de marketing pour la santé des femmes Aspira en 2023 se sont élevés à 9,2 millions de dollars.

• Coûts de l'équipe de vente directe: 4,6 millions de dollars
• Campagnes marketing: 2,7 millions de dollars
• Marketing numérique et publicité: 1,9 million de dollars

Processus de conformité réglementaire et de certification

Les dépenses de conformité réglementaire pour 2023 étaient de 3,6 millions de dollars.

Activité de conformité	Frais
Coûts de soumission de la FDA	1,2 million de dollars
Maintenance de certification	1,4 million de dollars
Frais juridiques et de consultation	1,0 million de dollars

Aspira Women's Health Inc. (AWH) - Modèle commercial: Strots de revenus

Ventes et licences de test de diagnostic

En 2023, Aspira Women's Health a déclaré un chiffre d'affaires de test de diagnostic de 5,3 millions de dollars. Les tests OVA1 et ROM de l'entreprise ont généré des revenus de licence spécifiques des prestataires de soins de santé.

Test de diagnostic	Revenus annuels (2023)	Pénétration du marché
Test OVA1	3,2 millions de dollars	62 systèmes de soins de santé
Test des Roms	2,1 millions de dollars	48 systèmes de soins de santé

Remboursement des assureurs

Aspira a obtenu des accords de remboursement avec plusieurs assureurs en 2023.

• Taux de remboursement de Medicare: 1 250 $ par test de diagnostic
• Couverture d'assurance privée: 85% des principaux réseaux de soins de santé
• Remboursement moyen par test: 875 $

Frais de service clinique

Les revenus des services cliniques pour 2023 ont totalisé 4,7 millions de dollars, dérivé des services de test de diagnostic et de consultation.

Type de service	Revenu	Volume
Dépistage du cancer de l'ovaire	3,5 millions de dollars	4 200 tests
Services de consultation	1,2 million de dollars	1 800 consultations

Grants de recherches et collaborations

Le financement de la recherche en 2023 s'élevait à 2,9 millions de dollars de diverses sources.

• Grant des National Institutes of Health (NIH): 1,5 million de dollars
• Collaboration de recherche privée: 800 000 $
• Partenariats des établissements académiques: 600 000 $

Licence de propriété intellectuelle

Les licences de propriété intellectuelle ont généré 1,6 million de dollars de revenus en 2023.

Catégorie IP	Revenus de licence	Nombre de licences
Algorithmes de test de diagnostic	1,2 million de dollars	7 licences
Technologie des tests moléculaires	$400,000	3 licences

Aspira Women's Health Inc. (AWH) - Canvas Business Model: Value Propositions

The core value proposition of Aspira Women's Health Inc. (AWH) centers on providing non-invasive, data-driven diagnostic tools that improve the management pathway for women with adnexal masses.

Non-invasive, blood-based ovarian cancer risk assessment

Aspira Women's Health Inc. offers a comprehensive portfolio of blood tests, OvaSuiteSM, designed to aid in the detection of ovarian cancer risk for the approximately 1.2 million American women diagnosed with an adnexal mass each year. The company reported total product revenues of $2.3 million for the third quarter of 2025, with gross margins reaching 64.1% for the nine months ended September 30, 2025.

OvaWatch: 99% negative predictive value for indeterminate masses

OvaWatch℠ is positioned for women where an initial clinical assessment indicates the mass is indeterminate or benign, supporting decisions where surgery may be premature or unnecessary. The test provides a negative predictive value of 99%.

Ova1Plus: Pre-surgical assessment of malignancy risk for adnexal masses

Ova1Plus® is a proprietary reflex process combining two FDA-cleared tests, Ova1® and Overa®, specifically for patients with adnexal masses that are planned for surgery. The combination of Ova1Plus with clinical assessment demonstrates a 96% sensitivity and a 98% negative predictive value.

The comparative performance against the standard CA-125 marker highlights the precision of Ova1Plus:

Performance Metric	Ova1Plus (with clinical assessment)	CA-125 Alone
Detection of Early-Stage Malignancy Risk (Stage I and II)	Includes detection of 63% missed by CA-125	Misses 63% of Stage I and II risk
Detection of Ovarian Cancer Risks	Detects 59% more risks missed	Baseline for comparison

Improved patient outcomes through early, precise risk stratification

The value here is in refining the management plan before an invasive procedure. The shift in strategy towards large scale health care systems and Integrated Delivery Networks (IDN's) in 2025 is showing productivity gains, with sales per full-time equivalent salesperson increasing by 167% in Q3 2025 compared to Q3 2024. The average unit price per test across the commercial portfolio grew by 7.0% year-over-year in Q3 2025.

Key clinical differentiators include:

• Ova1Plus detects 59% more ovarian cancer risks missed by CA-125 alone.
• Ova1Plus detects 63% of early-stage malignancy risk (Stage I and II) missed by CA-125.
• OvaWatch provides a 99% negative predictive value.

Cost savings for health systems by reducing unnecessary specialist referrals

Precise risk stratification directly translates to resource optimization within health systems. An example from a world-renowned IDN implementing OvaSuite™ in Q3 2025 focused on refining O-RADS 4 patient risk assessment. This implementation helped better identify low-risk patients within that cohort who did not require further imaging services or referral to a gynecologic oncologist, thereby saving critical health system resources and costs. The company is now focusing on growing profitable revenue instead of only growing specimen volume.

Aspira Women's Health Inc. (AWH) - Canvas Business Model: Customer Relationships

Dedicated assistance and clinical support for IDN integration is a core focus following the Q1 2025 strategy reset. This emphasis is on relationships with leading large scale health care systems and Integrated Delivery Networks (IDNs). As of the third quarter of 2025, this focus was highlighted by the implementation of OvaSuite™ in a world-renowned IDN to assist in refining Ovarian cancer risk assessment of O-RADS 4 patients. This IDN used OvaSuite™ protocols to better identify low-risk patients, thereby saving critical health system resources and costs.

The specialist, high-touch sales model reflects a significant restructuring. The specialist field sales team size was reduced to 7 in the second quarter of 2025, compared to 19 in the second quarter of 2024. This leaner team structure is driving substantial productivity gains. Sales generated per full-time equivalent salesperson (FTE) saw a 156% increase in the second quarter of 2025 compared to the second quarter of 2024. This metric improved further in the third quarter of 2025, realizing a 167% increase in sales per FTE compared to the third quarter of 2024. Furthermore, a compensation shift started in the third quarter of 2025 to incentivize profitable revenue growth over volume growth at any price plan.

Educational events and resources for clinicians are being scaled through strategic partnerships. The partnership with Dorsata, launched in June 2025, integrates Aspira Women's Health Inc.'s OvaSuite tests into Dorsata's platform. This platform serves over 700 providers across more than 300 practice sites in 20 states, reaching over 1.5 million patients. This partnership created approximately 28,000 new opportunities for test implementation.

Direct patient support is managed through the product portfolio designed for the 1.2+ million American women diagnosed with an adnexal mass each year. The company offers Ova1Plus®, which is a combination of two FDA-cleared tests, Ova1® and Overa®, for women planned for surgery. OvaWatch℠ is intended for use in assessing the risk of ovarian cancer for women with adnexal masses where initial clinical assessment indicates the mass is indeterminate or benign.

Here's a quick look at the sales force efficiency metrics as of late 2025:

Metric	Value (Q2 2025 vs Q2 2024)	Value (Q3 2025 vs Q3 2024)
Specialist Field Sales Team Size	7 (Q2 2025) vs 19 (Q2 2024)	Not specified
Increase in Sales per FTE	156% increase	167% increase

The reach through the Dorsata partnership as of mid-2025 includes:

• Providers served: Over 700
• Practice sites reached: Over 300
• States covered: 20
• Patients reached: Over 1.5 million
• New test implementation opportunities created: 28,000

The company is focused on delivering products that allow healthcare providers to stratify risk, facilitate early detection, and optimize treatment plans.

Aspira Women's Health Inc. (AWH) - Canvas Business Model: Channels

You're looking at how Aspira Women's Health Inc. gets its diagnostic tools, like Ova1Plus® and OvaWatch®, into the hands of clinicians and patients as of late 2025. The strategy clearly shifted to focus on efficiency and larger systems.

Specialist field sales team targeting physicians and IDNs

The direct sales channel saw a significant restructuring. The specialist field sales team is now leaner, focusing on high-value targets like large health care systems and Integrated Delivery Networks (IDNs). This change reflects a strategic pivot away from pure volume.

Here's a look at the team size and productivity metrics:

Metric	Value	Period/Context
Specialist Field Sales Team Size	7 FTEs	Q2 2025
Specialist Field Sales Team Size (Comparison)	19 FTEs	Q2 2024
Sales per FTE Increase	167% increase	Q3 2025 compared to Q3 2024
Active Prescribing Providers	4,000 providers	As of June 2025

This smaller team delivered results, though the overall OvaSuite test volume saw a dip, which management attributed to this strategic reset.

Direct sample submission to Aspira Labs, Inc.

Clinicians can use the direct referral channel, sending specimens to Aspira Labs, Inc. for processing. Aspira Labs, Inc. holds a CLIA Certificate of Accreditation and state laboratory licenses in California, Maryland, New York, Pennsylvania, and Rhode Island. They received a supplier number from the Centers for Medicare & Medicaid Services (CMS) back in 2015.

Test volume data shows the direct lab channel's recent activity:

• OvaSuite tests performed decreased 5% for the three months ended September 30, 2025.
• Volume was 5,727 tests for the three months ended September 30, 2025.
• Volume was 6,001 product tests for the same period in 2024.
• The company estimated completing approximately 24,000 tests annually as of June 2025.

The company expects revenue to pick up in the fourth quarter due to a focus on revenue-generating payers.

Aspira Synergy platform for decentralized testing access

The Aspira Synergy platform is a key channel for decentralized testing access, allowing marketing of OvaSuite tests to laboratories. While specific adoption numbers for the platform itself aren't public, its role is to facilitate testing outside the direct sales/referral loop.

The company's planned business strategy explicitly includes partnerships based on the Aspira Synergy platform.

Strategic partnerships with healthcare practice networks (e.g., Dorsata)

Strategic partnerships are a major focus for accelerated adoption, exemplified by the collaboration with Dorsata. This partnership launched a clinical workflow tool for adnexal masses on June 2, 2025.

The reach through this specific partnership is substantial:

Partnership Reach Metric	Value	Context
Dorsata Providers Reached	More than 700 women's health providers	As of June 2025
Practice Sites Reached	Over 300 practice sites	As of June 2025
States Covered	20 states	As of June 2025
Patients Impacted Annually	Over 1.5 million patients	Annually via Dorsata platform
Increase in Provider Access	700 providers	Directly from the Dorsata partnership

This partnership added a 17.5% boost to the total provider access pool at that time. It's a clear example of how Aspira Women's Health Inc. is using integrated software to drive channel efficiency.

Aspira Women's Health Inc. (AWH) - Canvas Business Model: Customer Segments

You're trying to map out exactly who Aspira Women's Health Inc. (AWH) is selling its OvaSuite diagnostics to as of late 2025. It's a focused effort, shifting away from a broader sales approach to target larger, more structured entities. Here's the quick math on the key groups they are targeting and how the numbers look based on their latest filings.

Gynecologists and gynecologic oncologists (primary prescribers)

These are the frontline clinicians who order the tests-OvaWatch and Ova1Plus-to manage patients presenting with adnexal masses. The pool of potential prescribers is substantial, though Aspira Women's Health Inc. is clearly streamlining its engagement efforts.

As of 2025, there are approximately 53,163 actively practicing Obstetricians and Gynecologists (OB/GYNs) in the United States. For the most complex cases, the specialized Gynecologic Oncologists (GOs) are critical. As of October 2025, the total number of oncologists tracked in the U.S. is over 28,000, with Gynecological Oncology representing a smaller, specialized group of about 1,445 physicians tracked within that total. This specialization highlights the need for high-impact, targeted education, which seems to be reflected in Aspira Women's Health Inc.'s reduced but seemingly more productive sales force.

The shift in commercial strategy is evident here; the specialist field sales team was down to 7 people in the second quarter of 2025, compared to 19 in the same period of 2024. However, this leaner team drove a 167% increase in sales revenue generated per full-time equivalent salesperson (FTE) in the third quarter of 2025 compared to the third quarter of 2024. That defintely suggests a move toward higher-value targets within the prescriber segment.

Women with adnexal masses (over 1.2 million US women annually)

This is the ultimate patient population that drives demand for OvaSuite. Aspira Women's Health Inc. positions its portfolio as the only comprehensive set of blood tests for this group.

The total addressable market is consistently cited as the 1.2+ million American women diagnosed with an adnexal mass each year. This is the raw volume that underpins the entire business case. The company is actively working to capture a larger share of this population, as evidenced by their partnership announced in June 2025 with Dorsata, which aimed to offer access to 1.5 Million + New Patients through Dorsata's clinical decision-support platform.

Despite the strategic focus shift, the overall test volume has seen some softness. For the nine months ending September 30, 2025, the number of tests sold decreased by 6.4% year-over-year, even as the average unit price (AUP) grew by 7.0% in the third quarter of 2025.

Large-scale health care systems and Integrated Delivery Networks (IDNs)

This segment represents the strategic pivot for Aspira Women's Health Inc. in 2025. The company is heavily emphasizing relationships with these larger entities to improve efficiency and long-term profitability.

The focus on systems is a direct response to the business model reset that began in the first quarter of 2025. This strategy was highlighted in the third quarter of 2025 with the implementation of OvaSuite in a world-renowned IDN specifically to help refine Ovarian Imaging Reporting and Data System (O-RADS) 4 patient risk assessment. Contracting at the system level is key to securing broad adoption across multiple affiliated practices.

Commercial insurance companies and government payers (Medicare)

Payer coverage dictates patient access and, ultimately, revenue realization. Aspira Women's Health Inc. works with payers to ensure their tests are covered, minimizing out-of-pocket costs for patients.

While specific 2025 coverage numbers aren't fully detailed, prior progress indicates the importance of this segment. In 2024, new Anthem contracts were reported to potentially add up to 16 million covered lives, and Medicaid coverage expanded to include fee schedules in nine states. For Medicare, reimbursement rates for MAAA (Multianalyte Assays with Algorithmic Analyses) CPT codes were extended through 2024, with the next evaluation scheduled for 2025.

The financial results show the commercial portfolio's AUP grew 11% year-over-year for Ova1Plus and 16% for OvaWatch in the second quarter of 2025, suggesting successful pricing power, likely supported by payer wins.

To keep track of where the revenue is coming from relative to the market size, here's a snapshot of the key figures we're tracking for late 2025:

Segment/Metric	Quantifiable Data Point	Source Year/Period
Annual Target Patient Population (Adnexal Masses)	1.2+ Million Women Annually	2025 Data
Total U.S. Active OB/GYNs	53,163 Physicians	2025 Data
U.S. Gynecologic Oncologists (Approx.)	1,445 Physicians	October 2025 Data
Total Product Revenue (Q3)	$2.3 Million	Q3 2025
Sales Force Size (FTEs)	7 (Specialist Field Sales)	Q2 2025
Sales Productivity (Revenue per FTE)	167% Increase vs. Q3 2024	Q3 2025
OvaWatch AUP Growth	16% Year-over-Year	Q2 2025

You should keep an eye on the test volume trend. While AUP is up, the number of tests sold for the first nine months of 2025 was down 7.3% compared to the first nine months of 2024. That volume dip, alongside the sales team reduction, confirms the transitional nature of their current commercial model.

Finance: draft 13-week cash view by Friday.

Aspira Women's Health Inc. (AWH) - Canvas Business Model: Cost Structure

You're looking at the cost side of the Aspira Women's Health Inc. (AWH) business model as of late 2025. Management has clearly been focused on aggressive cost containment, which shows up significantly in the year-to-date figures.

The total operating expenses for the nine months ended September 30, 2025, landed at $11.1 million. This is a substantial reduction from the $16.8 million reported for the same nine-month period last year, representing a 34.0% decrease overall. This drop is the result of targeted cuts across the board, which is exactly what you want to see when a company is resetting its commercial strategy.

Here is how the major operating expense categories shifted for the nine months ended September 30, 2025, compared to the prior year:

• Selling expenses saw a significant reduction of $3.7 million.
• General and administrative (G&A) costs were down by $1.7 million.
• Research and development (R&D) expenses were reduced by $0.4 million.

The primary driver for these reductions was headcount reductions and other cost containment measures across the organization.

When we look at the Cost of Revenue (COGS) for lab operations and materials, we can derive the total cost based on reported revenue and gross profit for the nine months ended September 30, 2025. With nine-month revenue at approximately $6.99 million and gross profit at approximately $4.5 million, the total Cost of Revenue for the nine months was approximately $2.49 million ($6.99 million minus $4.5 million). For the three months ended September 30, 2025, the Cost of product revenue was explicitly reported as $922,000.

The efficiency gains are also reflected in the gross margin performance. Gross margins for the nine months ended September 30, 2025, improved to 64.1%, up from 58.4% in the same period last year, with gross profit reaching approximately $4.5 million.

To give you a clearer picture of the expense components and their relative scale for the nine months ended September 30, 2025, based on the reported decreases:

Expense Category	Nine Months Ended Sept 30, 2025 (Total OpEx)	Year-over-Year Decrease (Nine Months)
Total Operating Expenses	$11.1 million	$5.7 million
Selling Expenses	Not Stated	$3.7 million decrease
General and Administrative (G&A) Costs	Not Stated	$1.7 million decrease
Research and Development (R&D) Expenses	Not Stated	$0.4 million decrease

G&A costs include personnel-related expenses, professional fees, and other infrastructure costs, such as legal, finance, and accounting expenses, which would encompass regulatory compliance costs.

Finance: review Q4 2025 expense run-rate against the nine-month annualized run rate by Tuesday.

Aspira Women's Health Inc. (AWH) - Canvas Business Model: Revenue Streams

The revenue streams for Aspira Women's Health Inc. are primarily derived from product sales of their diagnostic tests, supplemented by capital infusions from equity financing activities.

Product revenue is generated from the commercial portfolio, which includes non-invasive Ovarian cancer risk assessment diagnostics marketed as Ova1Plus and OvaWatch, together offered as OvaSuite.

The company has been strategically shifting focus towards growing profitable revenue, which includes efforts to maximize revenue realized from specimens performed by the lab, involving evaluation of payer contracts and billing practices.

Here are the key financial metrics related to revenue streams as of late 2025:

Revenue Metric	Amount / Detail	Date Reference
Total Product Revenue (Nine Months)	$7.0 million	Ended September 30, 2025
Trailing 12-Month Revenue (LTM)	$9.34 million	As of September 30, 2025
Q3 2025 Product Revenue	$2.31 million	For the three months ended September 30, 2025
OvaSuite Test Volume (Q3 2025)	5,727 tests	For the three months ended September 30, 2025
Average Unit Price (AUP) Growth (Q3 2025 vs. prior year)	7.0%	For the commercial product portfolio

Capital raises represent a distinct, non-operational revenue stream used to support commercial activities and working capital. In September 2025, Aspira Women's Health Inc. secured significant funding:

• Private Investment in Public Equity (PIPE) amount: $2.95 million.
• Unsolicited warrant exercise proceeds: $112 thousand.
• Total equity capital infusion announced: $3.06 million.

The reimbursement component is tied directly to the product revenue stream, driven by payer contracts and coverage decisions, such as the Novitas Local Coverage Determination (LCD) for Medicare, which supports the utilization of their tests.

The company's focus on growing profitable revenue is highlighted by the change in the commercial model, emphasizing relationships with large scale health care systems and Integrated Delivery Networks (IDN's).

The product revenue for the third quarter of 2025 was relatively flat compared to the prior year's third quarter, which was $2.26 million, despite a significant reset in business model and market strategies beginning in the first quarter of 2025.